Body composition · BELIEVE
Losing more fat.
Keeping more lean tissue.
The BELIEVE trial asks what changes when weight-loss treatment also targets the pathways that regulate muscle. The answer goes beyond the number on the scale.
The short version
In BELIEVE, adding experimental bimagrumab to semaglutide increased fat loss and reduced lean-tissue loss. Some lean tissue was still lost. Lean-tissue preservation does not establish consistent improvements in strength or longer life. [1]
What did BELIEVE test?
The phase 2 trial randomized 507 adults with obesity, or overweight with an obesity-related complication, excluding diabetes. Bimagrumab blocks activin type II receptors, affecting myostatin and activin signaling; it is broader than a direct myostatin inhibitor. The main report appeared in Nature Medicine on March 2, 2026. [1]
What changed at 48 weeks?
The treatment-regimen analysis reported these model-adjusted averages. [1]
| Outcome | Bimagrumab + semaglutide | Semaglutide alone |
|---|---|---|
| Body weight | −17.8 kg | −14.2 kg |
| Fat mass | −15.6 kg | −9.6 kg |
| Lean mass | −1.3 kg | −3.9 kg |
Common bimagrumab adverse events included cramps, diarrhea and acne. Semaglutide treatment was open-label. [1]
Does more lean tissue mean better function?
DXA lean mass is not a direct measure of strength. Grip strength improved significantly versus placebo in only one combination arm. [1]
For someone interested in aging well, the useful question is whether treatment ultimately helps people stay capable and independent. A more favorable scan cannot answer that question by itself. Strength, movement, falls and survival each need their own evidence.
What happened after treatment stopped?
A Lilly presentation at EASD in September–October 2026 described 24 weeks of follow-up after treatment withdrawal. By week 96, fat and lean-tissue measures were moving back toward baseline. Some metabolic changes persisted; LDL cholesterol, which had risen during bimagrumab treatment, declined after withdrawal. These are sponsor conference findings, separate from the peer-reviewed main report. [3]
Durability belongs alongside benefit and tolerability. A result during treatment cannot, by itself, tell a reader what happens years later or after stopping.
How is this different from COURAGE?
COURAGE studied trevogrumab, which directly targets myostatin, with semaglutide. Some groups also received garetosmab, which targets activin A. It is a related research program with different treatments.
COURAGE’s peer-reviewed report was published on November 11, 2026. [4] Read the COURAGE explainer for dose-specific uncertainty, separate combination safety findings and the limits of the available abstract.
A useful question to take away
“When my weight changes, how are we checking strength and physical function as well as body composition?”
Bimagrumab remains investigational. This article explains research; personal treatment decisions belong in a conversation with a licensed clinician.
Follow the evidence as it develops.
Explore new findings, the questions they answer and the limits that remain.
Read more research updatesRead the sources
- BELIEVE: bimagrumab and semaglutide in obesityNature Medicine · March 2, 2026 · Peer-reviewed phase 2 trial. Table 2 reports the 48-week treatment-regimen analysis. DOI: 10.1038/s41591-026-04204-0.
- BELIEVE trial registrationClinicalTrials.gov · NCT05616013 · Study design and reported results.
- BELIEVE: six-month withdrawal extensionLilly presentation · EASD, September 28–October 2, 2026 · Sponsor conference evidence.
- COURAGE: published reportThe Lancet · November 11, 2026 · Published author abstract; full text and supplement not reviewed.
BELIEVE sources checked November 7, 2026; COURAGE reference checked November 12, 2026. Annume’s interpretation is that the quality and durability of weight loss deserve attention alongside its size.
Prepared with AI assistance. No article-specific clinician review is credited. Read our editorial standards and correction policy.